Published in Antimicrob Agents Chemother on March 01, 1990
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes. Antimicrob Agents Chemother (1992) 1.60
Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani. Antimicrob Agents Chemother (2011) 1.45
Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother (1991) 1.39
Rhinocerebral mucormycosis treated with 32 gram liposomal amphotericin B and incomplete surgery: a case report. BMC Infect Dis (2001) 1.30
Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis. Antimicrob Agents Chemother (1994) 1.20
Comparative in vitro effects of liposomal amphotericin B, amphotericin B-deoxycholate, and free amphotericin B against fungal strains determined by using MIC and minimal lethal concentration susceptibility studies and time-kill curves. Antimicrob Agents Chemother (1991) 1.19
Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother (1992) 1.14
Influence of diet on experimental toxicity of amphotericin B deoxycholate. Antimicrob Agents Chemother (1994) 1.11
Trial of glucose versus fat emulsion in preparation of amphotericin for use in HIV infected patients with candidiasis. BMJ (1992) 1.10
Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index. Antimicrob Agents Chemother (1997) 1.08
Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis (2011) 1.07
Pharmacokinetics of conventional formulation versus fat emulsion formulation of amphotericin B in a group of patients with neutropenia. Antimicrob Agents Chemother (1996) 0.98
In vitro models for studying toxicity of antifungal agents. Antimicrob Agents Chemother (1992) 0.97
On the one-sided action of amphotericin B on lipid bilayer membranes. J Gen Physiol (1996) 0.95
Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ (1994) 0.93
Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother (1995) 0.91
Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients. Antimicrob Agents Chemother (1994) 0.90
Inhibition of amphotericin B (Fungizone) toxicity to cells by egg lecithin-glycocholic acid mixed micelles. Antimicrob Agents Chemother (1990) 0.87
Aerosolized liposomal amphotericin B for treatment of pulmonary and systemic Cryptococcus neoformans infections in mice. Antimicrob Agents Chemother (1992) 0.86
Liposomes and nanoparticles as vehicles for antibiotics. Infection (1991) 0.81
Deleterious effect of serum proteins on the amphotericin B-induced potentiation of cisplatin in human colon cancer cells. Br J Cancer (1994) 0.77
New challenges to the therapy of systemic fungal infections. Trans Am Clin Climatol Assoc (1996) 0.75
Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomedicine (2015) 0.75
In search of the amazing technicolour dream coat for amphotericin B. Can J Infect Dis (1996) 0.75
How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochim Biophys Acta (1986) 4.22
Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B. J Infect Dis (1983) 3.86
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis (1985) 2.64
Treatment of murine cryptococcosis with liposome-associated amphotericin B. J Infect Dis (1982) 2.36
Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci U S A (1988) 2.22
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta (1984) 2.21
Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B. Antimicrob Agents Chemother (1987) 2.14
Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis (1989) 2.08
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B. J Clin Oncol (1987) 1.83
Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. J Antimicrob Chemother (1981) 1.82
Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Mol Pharmacol (1987) 1.51
An emulsion formulation of amphotericin B improves the therapeutic index when treating systemic murine candidiasis. J Infect Dis (1988) 1.43
Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. Eur J Cancer Clin Oncol (1988) 1.38
Liposome-encapsulated amphotericin B: a promising new treatment for disseminated fungal infections. Rev Infect Dis (1989) 1.28
Circular dichroism for the determination of amphotericin B binding to liposomes. Anal Biochem (1988) 1.19
Study of the effects of liposomal amphotericin B on Candida albicans, Cryptococcus neoformans, and erythrocytes by using small unilamellar vesicles prepared from saturated phospholipids. Antimicrob Agents Chemother (1989) 1.11
Application of differential spectra in the ultraviolet-visible region to study the formation of amphotericin B-sterol complexes. Biochim Biophys Acta (1980) 1.08
Effect of the aggregation state of amphotericin B on its interaction with ergosterol. Biochem Cell Biol (1988) 1.08
Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity in rabbits. Antimicrob Agents Chemother (1985) 1.07
Effect of the polar head structure of polyene macrolide antifungal antibiotics on the mode of permeabilization of ergosterol- and cholesterol-containing lipidic vesicles studied by 31P-NMR. Mol Pharmacol (1986) 1.06
Effects of the detergent sucrose monolaurate on binding of amphotericin B to sterols and its toxicity for cells. Biochem Biophys Res Commun (1988) 1.01
Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics. J Infect Dis (1986) 0.98
Effect of attachment of anticandidal antibody to the surfaces of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrob Agents Chemother (1989) 0.94
Toxicity of solubilized and colloidal amphotericin B formulations to human erythrocytes. J Pharm Pharmacol (1988) 0.93
Development of amphotericin B liposomes bearing antibody specific to Candida albicans. Mycopathologia (1988) 0.91
The calcium channel antagonist, verapamil, potentiates the inhibitory action of morphine on intestinal and biliary motility. J Pharm Pharmacol (1987) 0.88
Variation in the susceptibility of strains of Staphylococcus aureus to oxacillin, cephalothin, and gentamicin. Antimicrob Agents Chemother (1976) 6.26
Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med (1997) 5.88
A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med (1979) 5.87
Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med (1992) 5.84
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis (2000) 5.53
Results of a survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin B. J Clin Microbiol (1986) 5.19
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin Infect Dis (1992) 4.98
Classification of Histoplasma capsulatum isolates by restriction fragment polymorphisms. J Bacteriol (1986) 4.55
Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A (1972) 4.09
Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med (1971) 4.02
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med (1970) 3.74
Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS (2000) 3.39
Comparison of the in vitro activities of HR756 with cephalothin, cefoxitin, and cefamandole. Antimicrob Agents Chemother (1978) 3.29
Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother (1990) 3.26
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Strategies in the treatment of systemic fungal infections. N Engl J Med (1980) 2.89
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals. Infect Control Hosp Epidemiol (1993) 2.65
Antimicrobial misuse in patients with positive blood cultures. Am J Med (1989) 2.45
Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med (1988) 2.44
An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet (2003) 2.43
Antibiotic synergism against Listeria monocytogenes. Antimicrob Agents Chemother (1972) 2.36
Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum. Science (1972) 2.31
Pulmonary cryptococcosis in patients without HIV infection. Chest (1999) 2.31
New fluorescence assay for the quantitation of fungi. J Clin Microbiol (1989) 2.26
Potentiation of the antifungal effects of antibiotics by amphotericin B. Antimicrob Agents Chemother (1972) 2.24
Rapid radiometric method of testing susceptibility of mycobacteria and slow-growing fungi to antimicrobial agents. Antimicrob Agents Chemother (1974) 2.22
Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med (1987) 2.20
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Antifungal agents useful in therapy of systemic fungal infections. Annu Rev Pharmacol Toxicol (1983) 2.11
Sex differences in nevirapine rash. Clin Infect Dis (2000) 2.09
In vitro activity of HR 756, a new cephalosporin, against Neisseria gonorrhoeae. Antimicrob Agents Chemother (1979) 2.09
Amphotericin B-induced oxidative damage and killing of Candida albicans. J Infect Dis (1986) 2.08
Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med (1970) 2.05
Typing of Histoplasma capsulatum by restriction fragment length polymorphisms in a nuclear gene. J Clin Microbiol (1992) 2.02
Interaction of plasma proteins and lipoproteins with amphotericin B. J Infect Dis (1984) 1.93
A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. N Engl J Med (1995) 1.89
Use of mitochondrial and ribosomal DNA polymorphisms to classify clinical and soil isolates of Histoplasma capsulatum. Infect Immun (1989) 1.85
Comparison of the separation of Candida albicans chromosome-sized DNA by pulsed-field gel electrophoresis techniques. Nucleic Acids Res (1989) 1.79
Irreversible block of the mycelial-to-yeast phase transition of Histoplasma capsulatum. Science (1986) 1.78
Sensitive high-pressure liquid chromatographic assay for amphotericin B which incorporates an internal standard. Antimicrob Agents Chemother (1986) 1.77
Use of paromomycin for treatment of cryptosporidiosis in patients with AIDS. Clin Infect Dis (1993) 1.77
Antifungal action of amphotericin B in combination with other polyene or imidazole antibiotics. J Infect Dis (1982) 1.76
Membrane lipid perturbation modifies the set point of the temperature of heat shock response in yeast. Proc Natl Acad Sci U S A (1996) 1.76
Isolation, characterization, and sequencing of Candida albicans repetitive element 2. Gene (1992) 1.73
Variable expression of a yeast-phase-specific gene in Histoplasma capsulatum strains differing in thermotolerance and virulence. Infect Immun (1989) 1.70
Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agents Chemother (1979) 1.69
Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Eur J Clin Microbiol Infect Dis (1988) 1.68
Cell wall studies of Histoplasma capsulatum. Sabouraudia (1967) 1.68
Possible relationship of morphogenesis in pathogenic fungus, Histoplasma capsulatum, to heat shock response. Nature (1983) 1.67
Antifungal agents: recent developments. Annu Rev Microbiol (1977) 1.66
Correlation between pathogenicity and temperature sensitivity in different strains of Histoplasma capsulatum. J Clin Invest (1986) 1.65
Listeriosis in humans: an evaluation. J Infect Dis (1971) 1.63
Involvement of oxidative damage in erythrocyte lysis induced by amphotericin B. Antimicrob Agents Chemother (1985) 1.62
Amphotericin B. Old drug, new therapy.?2110. JAMA (1975) 1.61
Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr (1999) 1.61
Refractory mucosal candidiasis in patients with human immunodeficiency virus infection. Clin Infect Dis (1998) 1.60
Temperature-sensitive variants of Histoplasma capsulatum isolated from patients with acquired immunodeficiency syndrome. J Infect Dis (1990) 1.60
Characterization of the binding of amphotericin B to Saccharomyces cerevisiae and relationship to the antifungal effects. Antimicrob Agents Chemother (1974) 1.60
Antimicrobial susceptibility testing of six clinical isolates of Aspergillus. Antimicrob Agents Chemother (1976) 1.59
Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med (1995) 1.59
Cutaneous mycobacteriosis: analysis of 34 cases with a new classification of the disease. Medicine (Baltimore) (1981) 1.57
Histoplasmosis. An illustrative case with unusual vaginal and joint involvement. Arch Dermatol (1969) 1.55
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med (2008) 1.54
Synergistic effect of amphotericin B and 1,3-bis(2-chloroethyl)-1-nitrosourea against a transplantable AKR leukemia. Cancer Res (1974) 1.52
Bacteremia in hospitalized patients infected with the human immunodeficiency virus: a case-control study of risk factors and outcome. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.47
RNA metabolism during morphogenesis in Histoplasma capsulatum. J Gen Microbiol (1974) 1.45
Regulation of dimorphism in the pathogenic fungus Histoplasma capsulatum. Nature (1977) 1.44
A new therapeutic approach to Candida infections. A preliminary report. Arch Intern Med (1972) 1.42